Tag Archives: drug development

Washington Post: Crowdsourcing Medical Decisions

clinical-trial-article-115x76

On Monday, Ariana Eunjung Cha wrote about the difficult ethical issue of Compassionate Use, which allows a patient access to an unapproved treatment when others with similar requests are denied access. Arthur Caplan, director of the division of medical ethics at New York University’s Langone Medical Center, describes it as a moral dilemma that could not be ‘more troubling and impossible-to-resolve’. In the article, Caplan asserts that ‘it’s best for the company to focus on getting the Read More >

Health  |  1 Comment  |  Email This Post
Tags: , , , , , ,

TRIPs Has Delivered: Patent Agreement Increases Drug Development

US Patent Application

The TRIPs (Trade Related Aspects of Intellectual Property) Agreement, effective in 1996, has resulted in multiple benefits for public health. The last blog post reviewed Progressive Economy’s finding of TRIPS at 20. One additional benefit not mentioned in the article is the explosion of molecules in clinical development. The World Intellectual Property Indicators – 2012 Edition reveals an overall growth in patent applications around the world. The report finds that patent applications “worldwide doubled from Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

BIO Patient and Health Advocacy Summit: Patient-Focused Drug Development

95468934

Panelists in this morning’s opening session outlined strategies for the FDA to better engage the patient community to guide the drug development process. “Patients should be providing input and guidance throughout the entire drug review process,” said Marc Boutin, Executive VP and COO of the National Health Council. Boutin highlighted the improvements made through PDUFA V to open up and enhance the Agency’s interaction and engagement with patients. “Integrating our perspective into how drugs are Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Who Cares About ALS?

ALS

1,100 days. That’s the average amount of time a person survives following a diagnosis of ALS. That is because ALS is a progressive neurodegenerative disorder defined by the loss of both upper and motor neurons which in the clinic is characterized by the atrophy of nearly all a person’s muscles.  These 1,100 days aren’t pretty. Each person will progressively lose their ability to speak, move or eat on their own. Most people will die from Read More >

Health  |  4 Comments  |  Email This Post
Tags: , , , , ,

A Bright Future for Orphan Disease Indications

Chart

In celebration of National Rare Disease Day BIO’s Industry Analysis team took a look at recently-approved drugs in the BioMedTracker database with an orphan indication designation. Our research found that 2012 saw the greatest number of approvals of therapies for orphan indications going back all the way to 2000 (This count includes previously approved drugs with new, orphan indication approvals).   Overall, 24 therapies were approved in orphan indications last year, including drugs for Anthrax, Gaucher’s Read More >

Inside BIO Industry Analysis  |  2 Comments  |  Email This Post
Tags: , , , , , , , , ,